§ 13F · FUND PROFILE
Versant Venture Management, LLC.
Institutional filer · behavioral pattern: Other. Summary pending.
AUM · $82.1T (13F)Positions · 8Turnover · — · Q4Filed · Feb 12, 2026
CONCENTRATION
—
Top 10 holdings
NEW BUYS
0
No new positions
EXITS
0
No exits
SECTOR SHIFT
—
No prior quarter data
3YR HIT RATE
—
Top-5 overlap
§ 01 · TOP HOLDINGS
The book · Q4 2025
FILED FEB 12, 2026
| # | Ticker | Name | Shares | $ value | % port | Δ Q4 |
|---|---|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics, Inc. | 4.38M | $68.7T | 45.5% | −22% |
| 2 | LENZ | Lenz Therapeutics, Inc. | 2.66M | $42.5T | 28.1% | ±0% |
| 3 | JBIO | Jade Biosciences, Inc. | 1.53M | $23.5T | 15.6% | ±0% |
| 4 | CRSP | CRISPR Therapeutics AG | 149K | $7.8T | 5.2% | ±0% |
| 5 | CTNM | Contineum Therapeutics, Inc. | 543K | $6.2T | 4.1% | ±0% |
| 6 | SKYE | Skye Bioscience, Inc. | 2.01M | $1.5T | 1.0% | ±0% |
| 7 | OVASUSD | Tempest Therapeutics, Inc. | 270K | $774.2B | 0.5% | ±0% |
§ 02 · SECTOR ALLOCATION
Where the money is
Sector data pending
§ 03 · THE VERSANT SIGNAL
AC read
Versant Venture Management, LLC is a Other fund managing $82136.9 trillion in assets. The fund runs a focused portfolio of just 8 positions.
Read the full dossier →§ 04 · FILING HISTORY
Q-by-Q deltas
1 FILINGS
Q4 2025
Steady book
+0 buys · −0 exits · 0 changed
Q3 2025
Steady book
+0 buys · −0 exits · 0 changed
Q2 2025
Steady book
+0 buys · −0 exits · 0 changed
Q1 2025
Steady book
+0 buys · −0 exits · 0 changed